Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NORMALIZED Scripts Update for Week Ending 07/06
V TRx > GL TRx by more than 1,200 scripts
V NRx > GL NRx by more than 1,500 scripts
ATH Across the board in Numbers
ATH in TRx & NRx Market Share, both > 50% – 2nd ATH in Refills Market Share
V
TRx: 63,177 {vs 56,032; +12.75%} Sector +11.88% --- ATH --- (7,581,192 vs 6,723,789)
NRx: 29,986 {vs 25,190; +19.04%} Sector +16.44% --- ATH --- (3,598,269 vs 3,022,813)
Ref: 33,191 {vs 30,841; +7.62%} Sector +8.18% --- ATH (3,982,923 vs 3,700,976)
GenL
TRx: 61,948 {vs 55,679; +11.26%} (7,433,774 vs 6,681,517)
NRx: 28,467 {vs 24,967; +14.02%} (3,415,994 vs 2,996,076)
L
TRx: 1,240 {vs 1,236; +0.28%} (148,752 vs 148,342)
NRx: 461 {vs 438; +5.24%} (55,280 vs 52,526)
V TRx Market Share: 50.00% vs 49.61% --- ATH
V NRx Market Share: 50.90% vs 49.79% --- ATH
V Ref Market Share: 49.21% vs 49.46% --- 2nd ATH
HD
Risk of Total Events With Icosapent Ethyl - Can We Reduce It?
I am not sure this was mentioned earlier on the board. It's June-2019 edition published by JACC
Anyone has access to the full article?
http://www.onlinejacc.org/content/73/22/2803?download=true
Analysis: May-2019 vs 2018 & First 5M-2019 vs 2018
May-2019 vs. May-2018 (NORMALIZED Retail ONLY Data)
Amazing Year-On-Year Increase Across the Board; 76% increase in TRx & 85% increase in NRx & 69% increase in Refills
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year ~+15% TRx & ~+18% NRx & ~+12% Refills) and at the same time increasing its own Market Share
V
TRx: 261,008 {vs 148,261; +76.05%} – Sector +14.69% -- ATH (31,320,937 vs 17,791,365)
NRx: 124,153 {vs 67,104; +85.02%} – Sector +18.24% -- ATH (14,898,397 vs 8,052,488)
Ref: 136,855 {vs 81,157; +68.63%} – Sector +11.71% -- ATH (16,422,540 vs 9,738,877)
Gen L
TRx: 264,170 {vs 277,670; -4.86%} (31,700,430 vs 33,320,398)
NRx: 123,658 {vs 127,877; -3.30%} (14,838,959 vs 15,345,290)
L
TRx: 5,564 {vs 36,826; -84.89%} (667,687 vs 4,419,060)
NRx: 2,184 {vs 16,449; -86.72%} (262,105 vs 1,973,830)
V May-2019 NORMALIZED Retail ONLY TRx Market Share: 49.18% vs 32.04% in May-2018 --- ATH
V May-2019 NORMALIZED Retail ONLY NRx Market Share: 49.66% vs 31.74% in May-2018 --- ATH
V May-2019 NORMALIZED Retail ONLY Ref Market Share: 48.75% vs 32.29% in May-2018 --- ATH
1st 5 Month-2019 vs. 1st 5 Month-2018 (NORMALIZED Retail ONLY Data)
Again Amazing Year-On-Year Increase Across the Board & driving the whole sector up with it
V
TRx: 1,128,667 {vs 681,148; +65.70%} – Sector +12.93% --- ATH
NRx: 561,012 {vs 307,798; +82.27%} – Sector +22.45% --- ATH
Ref: 567,655 {vs 373,350; +52.04%} – Sector +5.21% --- ATH
Gen L
TRx: 1,331,774 {vs 1,339,664; -0.59 %}
NRx: 635,364 {vs 595,230; +6.74%}
L
TRx: 28,933 {vs 183,590; -84.24%}
NRx: 11,650 {vs 83,509; -86.05%}
V First 5M-2019 NORMALIZED Retail TRx Market Share: 45.34% vs 30.90% in First 5M-2018 -- ATH
V First 5M-2019 NORMALIZED Retail NRx Market Share: 46.44% vs 31.20% in First 5M-2018 --ATH
V First 5M-2019 NORMALIZED Retail Ref Market Share: 44.30% vs 30.66% in First 5M-2018 -- ATH
Total Monthly NORMALIZED Retail ONLY Data May-2019
Amazing Numbers – ATH Across the Board in Numbers & Market Share
1st month in which V NRx > GL NRx --- Next reading (i.e. June-2019 V will be GREATER than GL across the board)
V
TRx: 261,008 {vs 243,499; +7.19%} – Sector +3.58% -- ATH (31,320,937 vs 29,219,892)
NRx: 124,153 {vs 119,622; +3.79%} – Sector +0.80% -- ATH (14,898,397 vs 14,354,580)
Ref: 136,855 {vs 123,878; +10.48%} – Sector +6.19% -- ATH (16,422,540 vs 14,865,312)
Gen L
TRx: 264,170 {vs 263,223; +0.36%} (31,700,430 vs 31,586,768)
NRx: 123,658 {vs 126,149; -1.97%} (14,838,959 vs 15,137,851)
L
TRx: 5,564 {vs 5,658; -1.67%} (667,687 vs 679,000)
NRx: 2,184 {vs 2,231; -2.11%} (262,105 vs 267,767)
Monthly NORMALIZED Retail TRx Market Share: 49.18% vs 47.52% --- ATH
Monthly NORMALIZED Retail NRx Market Share: 49.66% vs 48.23 % --- ATH
Monthly NORMALIZED Retail Refills Market Share: 48.75% vs 46.86% --- ATH
BB on 11/06 next week
Sabre,
If i may, this is not the way to look at it
You should look at the monthly numbers
You say
NORMALIZED Scripts Update for Week Ending 31/05
V TRx > GL TRx
V NRx > GL NRx
V Refills > GL Refills
ATH in Refills Numbers
ATH in TRx & Refills Market Share – 2nd ATH in NRx Market Share
Short Week – Memorial Day
V
TRx: 56,032 {vs 58,686; -4.52%} Sector -5.03% --- (6,723,789 vs 7,042,278)
NRx: 25,190 {vs 27,884; -9.66%} Sector -9.57% --- (3,022,813 vs 3,346,037)
Ref: 30,841 {vs 30,802; +0.13%} Sector -0.99% --- ATH (3,700,976 vs 3,696,241)
GenL
TRx: 55,679 {vs 59,049; -5.71%} (6,681,517 vs 7,085,837)
NRx: 24,967 {vs 27,585; -9.49%} (2,996,076 vs 3,310,172)
L
TRx: 1,236 {vs 1,189; +3.95%} (148,342 vs 142,705)
NRx: 438 {vs 478; -8.52%} (52,526 vs 57,416)
V TRx Market Share: 49.61% vs 49.35% --- ATH
V NRx Market Share: 49.79% vs 49.84% --- 2nd ATH
V Ref Market Share: 49.46% vs 48.91% --- ATH
To All,
I would like to suggest that we all disregard the msgs from LLC (Most probably he's the same old pyrr or fraudulent sharma dr.... both down now couple of hundred of thousand)
Let's not give them the pleasure of replying back
Disregard all their msgs, do not block them, as it's always fun to read their msg. But do not interact with them.
1, 2, 3, 4 , ....10 posts without any reply to any of these msgs, they will disappear in due time
Just my opinion, hope you all agree
NORMALIZED Scripts Update for Week Ending 24/05
V NRx > GL NRx
V TRx just shy 363 from GL TRx (was 1,117 last week)
ATH Across the Board in Market Share
As mentioned last week, all things going forward normally, by Week ending 07/06 V NRx & TRx will be both > GL NRx & TRx
V
TRx: 58,686 {vs 58,094; +1.02%} Sector +0.31% --- 2nd ATH (7,042,278 vs 6,971,301)
NRx: 27,884 {vs 27,815; +0.25%} Sector -0.48% --- 3rd ATH (3,346,037 vs 3,337,844)
Ref: 30,802 {vs 30,279; +1.73%} Sector +1.02% --- 2nd ATH (3,696,241 vs 3,633,457)
GenL
TRx: 59,049 {vs 59,211; -0.27%} (7,085,837 vs 7,105,336)
NRx: 27,585 {vs 27,892; -1.10%} (3,310,172 vs 3,347,008)
L
TRx: 1,189 {vs 1,252; -5.03%} (142,705 vs 150,263)
NRx: 478 {vs 509; -6.04%} (57,416 vs 61,104)
V TRx Market Share: 49.35% vs 49.00% --- ATH
V NRx Market Share: 49.84% vs 49.48% --- ATH
V Ref Market Share: 48.91% vs 48.57% --- ATH
Retinadoc
Expected September 2019 -- Bodes well for Reduce-It FDA 27/28 September :):)
2 in 1
https://clinicaltrials.gov/ct2/show/NCT02926027
AMARIN TO PRESENT AT THE JEFFERIES 2019 HEALTHCARE CONFERENCE JUNE 06, 2019
May 30, 2019 BEDMINSTER, N.J., and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019, at 9:30 a.m. Eastern Time in New York City.
A live audio webcast of the presentation will be available at: http://www.amarincorp.com, and will be accessible at the same link for 30 days.
In its sNDA filing acceptance communication to Amarin, the FDA did not indicate whether it plans to hold an advisory committee (AdCom) meeting to discuss this application
U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication
For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190529:nGNX5w9JMk
- PDUFA date assigned is September 28, 2019, four months sooner than
expected
- Vascepa, assuming approval, will be first drug indicated to reduce
residual cardiovascular risk in patients with statin-managed LDL-C
cholesterol, but persistent elevated triglycerides, as studied in the landmark
REDUCE-IT™ cardiovascular outcomes study
- Cardiovascular disease is the No. 1 cause of death for U.S. men and women
- Amarin is accelerating plans for commercial expansion, based on Priority
Review designation
BEDMINSTER, N.J. and DUBLIN, Ireland, May 29, 2019 (GLOBE NEWSWIRE) --
Amarin Corporation plc (NASDAQ:AMRN) announced today that its supplemental
new drug application (sNDA) for Vascepa® (icosapent ethyl) capsules has been
accepted for filing and granted Priority Review designation by the U.S. Food
and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal
date assigned by the FDA for this sNDA is September 28, 2019. Because of the
Priority Review designation, the timing of this PDUFA date is four months
earlier than the anticipated standard ten-month review for applications.
Assuming FDA approval, Vascepa will be the first drug indicated to reduce
residual cardiovascular risk in patients with statin-managed LDL-C
cholesterol, but persistent elevated triglycerides, an important indicator of
cardiovascular disease. This is a serious health challenge experienced by
millions of people.
The FDA grants Priority Review designation to applications for drugs that, if
approved, have the potential to offer significant improvements in the
effectiveness and safety of the treatment of serious conditions when compared
to standard applications.
“We expect earlier approval of an expanded indication for Vascepa to lead to
faster improvements in care for millions of patients with residual
cardiovascular risk after statin therapy,” said John F. Thero, president and
chief executive officer of Amarin. “These patients will be the focus of our
planned expanded REDUCE-IT(TM) promotional efforts. We are very pleased that
the FDA has accepted our application and granted it priority review. We
believe the unprecedented REDUCE-IT results position Amarin to lead a
transformative change in clinical practice for preventative treatment of
cardiovascular disease, the leading cause of death for both men and women in
the United States. Our plans to significantly expand promotion of Vascepa
following label expansion are being accelerated to reflect the upcoming PDUFA
date."
sNDA Based on Landmark REDUCE-IT Trial
The sNDA for Vascepa is based on the landmark REDUCE-IT cardiovascular
outcomes study, primary results of which were published in The New England
Journal of Medicine in November 2018.(1) Additional results and analysis of
total recurrent events observed were subsequently published in the Journal of
American College of Cardiology in March 2019.(2 )Vascepa is currently
indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult
patients with severe (TG >500 mg/dL) hypertriglyceridemia, an important but
much smaller patient population than can be addressed with an approval of this
sNDA.
In REDUCE-IT, Vascepa achieved the primary endpoint with a 25% relative risk
reduction compared to placebo (95% confidence interval [CI], 0.68-0.83;
p<0.001) in the first occurrence of a major adverse cardiovascular event
(MACE) in the intent-to-treat population. In REDUCE-IT, MACE consisted of a
composite of cardiovascular death, nonfatal myocardial infarction (MI or heart
attack), nonfatal stroke, coronary revascularization (procedures such as
stents and by-pass) and unstable angina requiring hospitalization.
As further evidence of the robustness of the REDUCE-IT results, Vascepa
achieved the study’s key secondary endpoint with a 26% relative risk
reduction (HR, 0.74; 95% CI, 0.65-0.83; p<0.001) in 3-point MACE in the
intent-to-treat population consisting of a composite of cardiovascular death,
nonfatal heart attack and nonfatal stroke. Vascepa also achieved seven other
secondary endpoints in the pre-specified hierarchical order below the key
secondary endpoint, including a 20% relative risk reduction in cardiovascular
death compared to placebo (HR, 0.80; 95% CI, 0.66-0.98; p=0.03). REDUCE-IT, a
global study of 8,179 statin-treated adults with elevated CV risk, was
performed based on a special protocol assessment (SPA) agreement with the FDA.
In REDUCE-IT, adverse events occurring with Vascepa use at greater than 5% and
greater than placebo were: peripheral edema (6.5% Vascepa versus 5.0%),
although there was no increase in the rate of heart failure in Vascepa
patients; constipation (5.4% Vascepa versus 3.6%), although mineral oil, as
used as placebo, is known to lower constipation; and atrial fibrillation (5.3%
Vascepa versus 3.9%), although there were reductions in rates of cardiac
arrest, sudden death and myocardial infarctions observed in Vascepa patients.
More information on safety data associated with REDUCE-IT is provided below
and in the published results.
FDA Advisory Committee Update
In its sNDA filing acceptance communication to Amarin, the FDA did not
indicate whether it plans to hold an advisory committee (AdCom) meeting to
discuss this application. Amarin previously expressed that it believes an
AdCom meeting organized by the FDA in conjunction with its review of the
expanded label for Vascepa is likely. It is not uncommon for clarification on
this topic to be provided by the FDA later in its review process.
About Amarin
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical
company focused on developing therapeutics to improve cardiovascular health.
Amarin’s product development program leverages its extensive experience in
polyunsaturated fatty acids and lipid science. Vascepa (icosapent ethyl) is
Amarin's first FDA-approved drug and is available by prescription in the
United States, Lebanon and the United Arab Emirates. Amarin’s commercial
partners are pursuing additional regulatory approvals for Vascepa in Canada,
China and the Middle East. For more information about Amarin,
visit www.amarincorp.com.
More About REDUCE-IT
REDUCE-IT(1), an 8,179-patient cardiovascular outcomes study, was completed in
2018. REDUCE-IT was the first multinational cardiovascular outcomes study that
evaluated the effect of prescription pure EPA therapy as an add-on to statins
in patients with high cardiovascular risk who, despite stable statin therapy,
had elevated triglyceride levels (at least 135 mg/dL). A large portion of the
male and female patients enrolled in this outcomes study were diagnosed with
type 2 diabetes.
More information on the REDUCE-IT study results can be found
at www.amarincorp.com.
About Cardiovascular Disease
Worldwide, cardiovascular disease (CVD) remains the No. 1 killer of men and
women. In the United States CVD leads to one in every three deaths – one
death approximately every 38 seconds – with annual treatment cost in excess
of $500 billion.(3, 4)
Multiple primary and secondary prevention
(https://www.globenewswire.com/Tracker?data=nVLG2-Ox7RReKJdzJ1Ns0o1o3ciZWW4EI1pbC7_BB3uvcPvynTZwXybACrhQAOXho191_GtnuxAPwFtYTMZF-h8IKlFQ74zgy6G40Jppde1uDLQodYB6U2o6VKjbTRoWXnYbsubjIHnMNK16M4nkTZvcQeH4s3PaSTLZ0E4dMk0tXX3wOuBgYk49_JR3wRO0WqGwfn_u5lO2viAyp9SDv7lk2qMR3vlEP8uZhGqW-wO3v82iZz77IyJJaCRrLAus14WrUyxSycZYcofQMqmUsKnxwAMtmg4hLChd9QwpYOTv2wwRQtlkdEBtclsDxNcWsNQ5eN6Q4HG5PxWb61ttw7NbeCcLQOMwqFLpsTk52jorW7l8SypyX1_sbUf_bxv_Lx8jjqPA7TDCuDoifkG4og==) trials
have shown a significant reduction of 25% to 35% in the risk
of cardiovascular events
(https://www.globenewswire.com/Tracker?data=NSa8Gduo1CAGjuUE8GvovWJQG12MTqqjlwFBI7mzACimiXEzqrQ580cwL2jxR4vU20MveHFRwc_2KHFHbhc_HbFGXjbya489bHqHhDmdotcTE3XzjqogkdiNlfrnI0qMDyc-Jw4WuuUIhV8l6TsXk07cKosNQ8Xt69W6iO6cW3haAOqCIC3TXkbLNDui-eNnbGE3z_ZiYC65LnDIO4zHbgZFci4tlehiRrdJZ7j4inVySzplyStAHEuBrs_WkqMLB3Wl-ipU8ekkNQwdX8EG1yhFG0gy68npzdExUqLX1oPrlhBI-4IErWysTu97Uz4gO91fFlKAe6HP4r6HN9Cz6dv9a-GtNrBGhJFgtEJ4vpM=) with statin
(https://www.globenewswire.com/Tracker?data=vZvzr92dh4T36OH_WYKguex6DELGFjE8hAjgMW2MQRxMebfK6ffFV-Xmu6l02lT9SBFShs2oVZFoiUaY2h5SS8tPKQUByjzJBIyi8vP7-TLjoDSCq2UulqBAvTrTNBzzdMQahScTQkwoGNaRWaHRe3d3Y02_WQ25gK1ua2gGgSl_2xgUfRaTW330FVVw0OkDfeKEWe9s1ZOHYXR8CtE0y4uiEJjh-Mh0fNft_PmVDAqEU_JLqx6n9RG6EXSRcr70zSy3Pk0pfk1C2wSMwUOWrA==) therapy,
leaving significant persistent residual risk despite the achievement of target
LDL-C levels.(5)
Beyond the cardiovascular risk associated with LDL-C, genetic, epidemiologic,
clinical and real-world data suggest that patients with elevated triglycerides
(TG) (fats in the blood), and TG-rich lipoproteins, are at increased risk for
cardiovascular disease.(6, 7, 8, 9)
About Vascepa (icosapent ethyl) Capsules
Vascepa (icosapent ethyl) capsules are a single-molecule prescription product
consisting of the omega-3 acid commonly known as EPA in ethyl-ester form.
Vascepa is not fish oil, but is derived from fish through a stringent and
complex FDA-regulated manufacturing process designed to effectively eliminate
impurities and isolate and protect the single molecule active ingredient from
degradation. Vascepa, known in scientific literature as AMR101, has been
designated a new chemical entity by the FDA. Amarin has been issued multiple
patents internationally based on the unique clinical profile of Vascepa,
including the drug’s ability to lower triglyceride levels in relevant
patient populations without raising LDL-cholesterol levels.
Indication and Usage Based on Current FDA-Approved Label (not including
REDUCE-IT results)
* Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce
triglyceride (TG) levels in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia.
* The effect of Vascepa on the risk for pancreatitis and cardiovascular
mortality and morbidity in patients with severe hypertriglyceridemia has not
been determined.
Important Safety Information for Vascepa Based on Current FDA-Approved Label
(not including REDUCE-IT results) (Includes Data from Two 12-Week Studies
(n=622) (MARINE and ANCHOR) of Patients with Triglycerides Values of 200 to
2000 mg/dL)
* Vascepa is contraindicated in patients with known hypersensitivity (e.g.,
anaphylactic reaction) to Vascepa or any of its components.
* In patients with hepatic impairment, monitor ALT and AST levels periodically
during therapy.
* Use with caution in patients with known hypersensitivity to fish and/or
shellfish.
* The most common reported adverse reaction (incidence >2% and greater than
placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no
reported adverse reaction >3% and greater than placebo.
* Adverse events and product complaints may be reported by calling
1-855-VASCEPA or the FDA at 1-800-FDA-1088.
* Patients receiving treatment with Vascepa and other drugs affecting
coagulation (e.g., anti-platelet agents) should be monitored periodically.
* Patients should be advised to swallow Vascepa capsules whole; not to break
open, crush, dissolve, or chew Vascepa.
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM
(https://www.globenewswire.com/Tracker?data=8KksWgL4hPjFB3hiR9YeMwhgMWWkdYaZyqtBrl_kBxu40X3RGz_rCdkZYtMq7qROIpX6duLeZxE1TsM2OwMpSs4ImDyRd937tKAcEAJ_VMBI2d8viUdvTiHzNYj5r9bcAc97BUKIucJTIwHv-2bYwFSxXU-jAWcJfjpTvpV1hVmRJ4DWve7GhwNjCxxJcp9aQR20WKnA4IwujJeQQeh_14Gs7rWesUYQLnaf55FHKFg=).
Important Safety Information for Vascepa based on REDUCE-IT, as previously
reported in The New England Journal of Medicine(1) publication of the
primary results of the REDUCE-IT study:
* Excluding the major adverse cardiovascular events (MACE) results described
above, overall adverse event rates in REDUCE-IT were similar across the statin
plus Vascepa and the statin plus placebo treatment groups.
* There were no significant differences between treatments in the overall rate
of treatment emergent adverse events or serious adverse events leading to
withdrawal of study drug.
* There was no serious adverse event (SAE) occurring at a frequency of >2%
which occurred at a numerically higher rate in the statin plus Vascepa
treatment group than in the statin plus placebo treatment group.
* Adverse events (AEs) occurring in 5% or greater of patients and more
frequently with Vascepa than placebo were:
– peripheral edema (6.5% Vascepa patients versus 5.0% placebo patients),
although there was no increase in the rate of heart failure in Vascepa
patients
– constipation (5.4% Vascepa patients versus 3.6% placebo patients),
although mineral oil, as used as placebo, is known to lower constipation,
and
– atrial fibrillation (5.3% Vascepa patients versus 3.9% placebo
patients), although there were reductions in rates of cardiac arrest, sudden
death and myocardial infarctions observed in Vascepa patients
* There were numerically more SAEs related to bleeding in the statin plus
Vascepa treatment group although overall rates were low with no fatal bleeding
observed in either group and no significant difference in adjudicated
hemorrhagic stroke or serious central nervous system or gastrointestinal
bleeding events between treatments.
* In summary, Vascepa was well tolerated with a safety profile generally
consistent with clinical experience associated with omega-3 fatty acids and
current FDA-approved labeling of such products.
Vascepa has been approved for use by the United States Food and Drug
Administration (FDA) as an adjunct to diet to reduce triglyceride levels in
adult patients with severe (≥500 mg/dL) hypertriglyceridemia. FDA has not
reviewed and opined on a supplemental new drug application related to
REDUCE-IT. FDA has not reviewed the information herein or determined whether
to approve Vascepa for use to reduce the risk of MACE. Nothing in this press
release should be construed as promoting the use of Vascepa in any indication
that has not been approved by the FDA.
Important Cautionary Information About These Data
Further REDUCE-IT data assessment and data release could yield additional
useful information to inform greater understanding of the trial outcome. For
example, detailed data assessment by regulatory authorities, such as the FDA
and Health Canada, will continue and take several months to complete and
announce. The final evaluation by regulatory authorities of the totality of
efficacy and safety data from REDUCE-IT may include some or all of the
following, as well as other considerations: new information or analyses
affecting the degree of treatment benefit on studied endpoints; study conduct
and data robustness, quality, integrity and consistency; additional safety
data considerations and risk/benefit considerations; and consideration of
REDUCE-IT results in the context of other clinical studies. Because regulatory
reviews are typically fluid and not definitive interactions between sponsor
and agency on individual elements of an application and related information,
Amarin does not plan to update investors on ongoing communications with
regulatory authorities. Amarin plans to announce the final outcome of such
regulatory reviews when appropriate.
Recurrent event analyses for the total primary endpoint events and for the
total key secondary endpoint in REDUCE-IT as published in the Journal of the
American College of Cardiology were conducted using a series of statistical
models. These analyses were tertiary or exploratory endpoints; most of the
models used were prespecified and one was post hoc. Each recurrent event
statistical model has inherent strengths and weaknesses, with no single model
considered definitive or outperforming the other models, and this is an
evolving field of science. Nonetheless, results from the total primary and
total key secondary endpoint events analyses are consistent across the various
recurrent event statistical models and are also consistent with the original
primary and secondary endpoint results. Together, the REDUCE-IT recurrent
event analyses and the original primary and key secondary endpoint analyses
support the robustness of the clinical benefit of Vascepa therapy in reducing
cardiovascular risk.
Forward-Looking Statements
This press release contains forward-looking statements, including expectations
regarding FDA regulatory review, the applicability and reliability of
REDUCE-IT results, expected outcome and timing of review elements and market
dynamics for Vascepa. These forward-looking statements are not promises or
guarantees and involve substantial risks and uncertainties. In addition,
Amarin's ability to effectively commercialize Vascepa will depend in part on
its ability to continue to effectively finance its business, efforts of third
parties, its ability to gain regulatory approvals, create market demand for
Vascepa through education, marketing and sales activities, to achieve market
acceptance of Vascepa, to receive adequate levels of reimbursement from
third-party payers, to develop and maintain a consistent source of commercial
supply at a competitive price, to comply with legal and regulatory
requirements in connection with the sale and promotion of Vascepa and to
maintain patent protection for Vascepa. Among the factors that could cause
actual results to differ materially from those described or projected herein
include the following: uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and approvals; the
risk that sales may not meet expectations and related cost may increase beyond
expectations; the risk that patents may not be upheld in patent litigation and
applications may not result in issued patents sufficient to protect the
Vascepa franchise. A further list and description of these risks,
uncertainties and other risks associated with an investment in Amarin can be
found in Amarin's filings with the U.S. Securities and Exchange Commission,
including its most recent quarterly report on Form 10-Q. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors
and the public using the company website (www.amarincorp.com), the investor
relations website (investor.amarincorp.com
(https://www.globenewswire.com/Tracker?data=8e-0UEylEl933TYvF2UeljxBFTh_BIKn2zZZavpvZbJ0KmQmz4aMMeQS08tucMVajkTpjcFAmni3kF5obie3r1q-cg41d3wX1T7tHOq9MNplxM5p5fwM0QwEM5_V0CW-Ka38jIhJ5c5AuD6X0iX8ulVsNWd3s_H-VZw4ppYjOG__3ZFkuRqOrNNM_jLYhdqWy9paF2S5fkTYAbZjiJDOjJ16EBWGCiZxdxiG3IYOvkTW4o9XFN3Vdkz1v-rU21fZcPwkS2ZrK9BUg0wKPzVw5Q==)),
including but not limited to investor presentations and investor FAQs,
Securities and Exchange Commission filings, press releases, public conference
calls and webcasts. The information that Amarin posts on these channels and
websites could be deemed to be material information. As a result, Amarin
encourages investors, the media, and others interested in Amarin to review the
information that is posted on these channels, including the investor relations
website, on a regular basis. This list of channels may be updated from time to
time on Amarin’s investor relations website and may include social media
channels. The contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels, shall not be
deemed incorporated by reference in any filing under the Securities Act of
1933.
References
(1) Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with
Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
(2 )Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total
Ischemic Events: From REDUCE-IT. J Am Coll Cardiol 2019. Epub ahead of print.
https://doi.org/10.1016/j.jacc.2019.02.032.
(3 )American Heart Association. 2018. Disease and Stroke Statistics-2018
Update.
(4 )American Heart Association. 2017. Cardiovascular disease: A costly burden
for America projections through 2035.
(5 )Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive
dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol.
2018;72(3):330-343.
(6 )Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal
pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145.
(7 )Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated
with increased cardiovascular events, medical costs, and resource use: A
real-world administrative claims analysis of statin-treated patients with high
residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.
(8 )Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic
cardiovascular disease - New insights from epidemiology, genetics, and
biology. Circ Res. 2016;118:547-563.
(9 )Nordestgaard BG, Varbo A. Triglycerides and cardiovascular
disease. Lancet. 2014;384:626–635.
Amarin Contact Information
Investor Relations:
Elisabeth Schwartz
Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
(https://www.globenewswire.com/Tracker?data=x9l9zIzZPjrw7wgmW0KIzTBF_zkX5hyUJ1jKde7JokQhLyUMcrzJlYvp1IE6yyY5rjic_u650Qf2J87RBl878XpfMlgocmJdKq8ezdV42fFumQi78-t0Njm9xkUZvQqCyr6LuUweuTH0XbPMVNZ4QDZD0kxcEP0iUoA76C7EuktNm7UsPRekhT_4DPLZnYuRCAZQTpqH8iZ_qEF4VsbKaRZ2enpFTqns4sByUybu9J_ZlKlwXOUalpBfLUYyiEBwsUZhxrz8ROPbG6kPFFILiw==)
Lee M. Stern
Trout Group
In U.S.: +1 (646) 378-2992
lstern@troutgroup.com
Media Inquiries:
Gwen Fisher
Corporate Communications
Amarin Corporation plc
In U.S.: +1 (908) 325-0735
PR@amarincorp.com
(https://www.globenewswire.com/NewsRoom/AttachmentNg/4e9ba297-8a1c-40bf-a8e8-4e7147b9d5de)
GlobeNewswire, Inc. 2019
Rank : positive
Related tickers: AMARIN CORPORATION PLC -ADR (AMRN) All English Language News: All English Language News Language: English language code Other: Corporate News Releases Region Related: United States of America Subject Related: Corporate News Releases (Global)
DM & Sabre
NORMALIZED Scripts Update for Week Ending 17/05
ATH Across the Board in Market Share
V NRx only shy 77 scripts of GL NRx while V TRx cutting the difference with GL TRx by almost 700 scripts on average per week
All things going forward normally, by Week ending 24/05 V NRx will be > GL NRx
All things going forward normally, by Week ending 07/06 V NRx & TRx will be both > GL NRx & TRx
V
TRx: 58,094 {vs 58,647; -0.94%} Sector -1.61% --- 3rd ATH (6,971,301 vs 7,037,681)
NRx: 27,815 {vs 28,240; -1.50%} Sector -2.57% --- 4th ATH (3,337,844 vs 3,388,767)
Ref: 30,279 {vs 30,408; -0.42%} Sector -0.72% --- 3rd ATH (3,633,457 vs 3,648,914)
GenL
TRx: 59,211 {vs 60,591; -2.28%} (7,105,336 vs 7,270,897)
NRx: 27,892 {vs 28,954; -3.67%} (3,347,008 vs 3,474,494)
L
TRx: 1,252 {vs 1,258; -0.47%} (150,263 vs 150,975)
NRx: 509 {vs 506; +0.57%} (61,104 vs 60,757)
V TRx Market Share: 49.00% vs 48.67% --- ATH
V NRx Market Share: 49.48% vs 48.94% --- ATH
V Ref Market Share: 48.57% vs 48.42% --- ATH
Scripts Update for Week Ending 17/05
Below the OLD scripts numbers as before, NOT NORMALIZED
ATH Across the Board in Market Share
V
TRx: 44,998 {vs 45,297; -0.66%} Sector -1.42% --- 3rd ATH
NRx: 18,403 {vs 18,612; -1.12%} Sector -2.30% --- 6th ATH
Ref: 26,595 {vs 26,685; -0.34%} Sector -0.79% --- 3rd ATH
GenL
TRx: 45,777 {vs 46,777; -2.14%}
NRx: 19,046 {vs 19,731; -3.47%}
L
TRx: 840 {vs 857; -1.98%}
NRx: 302 {vs 295; +2.37%}
V TRx Market Share: 49.12% vs 48.74% --- ATH
V NRx Market Share: 48.75% vs 48.17% --- ATH
V Ref Market Share: 49.37% vs 49.15% --- ATH
bio
NORMALIZED Scripts Update for Week Ending 10/05
ATH Across the Board in Market Share & 2nd ATH Across the Board in Numbers
V
TRx: 58,647 {vs 59,239; -1.00%} Sector -1.45% --- 2nd ATH (7,037,681 vs 7,108,668)
NRx: 28,240 {vs 28,399; -0.56%} Sector -0.87% --- 2nd ATH (3,388,767 vs 3,407,928)
Ref: 30,408 {vs 30,840; -1.40%} Sector -1.98% --- 2nd ATH (3,648,914 vs 3,700,740)
GenL
TRx: 60,591 {vs 61,728; -1.84%} (7,270,897 vs 7,407,358)
NRx: 28,954 {vs 29,327; -1.27%} (3,474,494 vs 3,519,259)
L
TRx: 1,258 {vs 1,302; -3.38%} (150,975 vs 156,258)
NRx: 506 {vs 479; +5.64%} (60,757 vs 57,514)
V TRx Market Share: 48.67% vs 48.45% --- ATH
V NRx Market Share: 48.94% vs 48.79% --- ATH
V Ref Market Share: 48.42% vs 48.14% --- ATH
Scripts Update for Week Ending 10/05
Below the OLD scripts numbers as before, NOT NORMALIZED
ATH Across the Board in Market Share & 2nd ATH Across the Board in Numbers
V
TRx: 45,297 {vs 45,748; -0.99%} Sector -1.51% --- 2nd ATH
NRx: 18,612 {vs 18,689; -0.41%} Sector -0.77% --- 2nd ATH
Ref: 26,685 {vs 27,059; -1.38%} Sector -2.03% --- 2nd ATH
GenL
TRx: 46,777 {vs 47,750; -2.04%}
NRx: 19,731 {vs 19,968; -1.19%}
L
TRx: 857 {vs 861; -0.46%}
NRx: 295 {vs 282; +4.61%}
V TRx Market Share: 48.74% vs 48.48% --- ATH
V NRx Market Share: 48.17% vs 48.00% --- ATH
V Ref Market Share: 49.15% vs 48.83% --- ATH
Total Monthly NORMALIZED Retail ONLY Data April-2019 & Year-On-Year Comparison
Total Monthly NORMALIZED Retail ONLY Data April-2019
Amazing Numbers – ATH Across the Board in Numbers & market Share
V
TRx: 243,499 {vs 229,970; +5.88%} – Sector +1.54% -- ATH (29,219,892 vs 27,596,430)
NRx: 119,622 {vs 117,214; +2.05%} – Sector -1.04% -- ATH (14,354,580 vs 14,065,633)
Ref: 123,878 {vs 112,757; +9.86%} – Sector +4.09% -- ATH (14,865,312 vs 13,530,797)
Gen L
TRx: 263,223 {vs 268,647; -2.02%} (31,586,768 vs 32,237,620)
NRx: 126,149 {vs 130,917; -3.64%} (15,137,851 vs 15,710,065)
L
TRx: 5,658 {vs 5,979; -5.36%} (679,000 vs 717,420)
NRx: 2,231 {vs 2,484; -10.18%} (267,767 vs 298,121)
Monthly NORMALIZED Retail TRx Market Share: 47.52% vs 45.58% --- ATH
Monthly NORMALIZED Retail NRx Market Share: 48.23% vs 46.77 % --- ATH
Monthly NORMALIZED Retail Refills Market Share: 46.86% vs 44.40% --- ATH
April-2019 vs. April-2018 (NORMALIZED Retail ONLY Data)
Amazing Year-On-Year Increase Across the Board, way better than non-normalized data; ~75% increase in TRx & ~90% increase in NRx
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year ~+16% TRx & ~+23% NRx) and at the same time increasing its own Market Share
V
TRx: 243,499 {vs 138,578; +75.71%} – Sector +16.06% -- ATH (29,219,892 vs 16,629,379)
NRx: 119,622 {vs 63,539; +88.27%} – Sector +23.16% -- ATH (14,354,580 vs 7,624,711)
Ref: 123,878 {vs 75,039; +65.08%} – Sector +10.10% -- ATH (14,865,312 vs 9,004,668)
Gen L
TRx: 263,223 {vs 268,044; -1.80%} (31,586,768 vs 32,165,279)
NRx: 126,149 {vs 121,894; +3.49%} (15,137,851 vs 14,627,293)
L
TRx: 5,658 {vs 34,859; -83.77%} (679,000 vs 4,183,098)
NRx: 2,231 {vs 15,931; -86.00%} (267,767 vs 1,911,747)
V Apr-2019 NORMALIZED Retail ONLY TRx Market Share: 47.52% vs 31.39% in Apr-2018 --- ATH
V Apr-2019 NORMALIZED Retail ONLY NRx Market Share: 48.23% vs 31.55% in Apr-2018 --- ATH
V Apr-2019 NORMALIZED Retail ONLY Ref Market Share: 46.86% vs 31.25% in Apr-2018 --- ATH
Monthly Retail ONLY Data April-2019 & Year-On-Year Comparison
Total Monthly Retail ONLY Data April-2019
NON–NORMALIZED Retail ONLY Data April-2019
Amazing Numbers – ATH Across the Board in Numbers & Market Share
V
TRx: 188,920 {vs 177,480; +6.45%} – Sector +1.30% -- ATH
NRx: 79,563 {vs 78,356; +1.54%} – Sector -2.23% -- ATH
Ref: 109,357 {vs 99,124; +10.32%} – Sector +4.05% -- ATH
Gen L
TRx: 203,220 {vs 209,340; -2.92%}
NRx: 86,188 {vs 91,078; -5.37%}
L
TRx: 3,766 {vs 4,000; -5.85%}
NRx: 1,316 {vs 1,448; -9.12%}
Monthly Retail TRx Market Share: 47.72% vs 45.41% --- ATH
Monthly Retail NRx Market Share: 47.62% vs 45.85% --- ATH
Monthly Retail Refills Market Share: 47.79% vs 45.07% --- ATH
April-2019 vs. April-2018 (Retail ONLY Data)
NON–NORMALIZED Retail ONLY Data April-2019 vs 2018
Amazing Year-On-Year Increase Across the Board, ~ 70% increase in TRx & ~ 80% increase in NRx
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year ~+13% TRx ~+18% NRx) and at the same time increasing its own Market Share
V
TRx: 188,920 {vs 111,697; +69.14%} – Sector +12.52% -- ATH
NRx: 79,563 {vs 44,560; +78.55%} – Sector +17.93% -- ATH
Ref: 109,357 {vs 67,137; +62.89%} – Sector +8.87% -- ATH
Gen L
TRx: 203,220 {vs 224,533; -9.49%}
NRx: 86,188 {vs 90,349; -4.61%}
L
TRx: 3,766 {vs 15,629; -75.90%}
NRx: 1,316 {vs 6,762; -80.54%}
V Apr-2019 Retail ONLY TRx Market Share: 47.72% vs 31.74% in Apr-2018 --- ATH
V Apr-2019 Retail ONLY NRx Market Share: 47.62% vs 31.45% in Apr-2018 --- ATH
V Apr-2019 Retail ONLY Ref Market Share: 47.79% vs 31.94% in Apr-2018 --- ATH
NORMALIZED Scripts Update for Week Ending 03/05
ATH Across the Board in Numbers & Market Share
Worth noting that Sector TRx reached a level never seen since early 2015
V
TRx: 59,239 {vs 54,606; +8.48%} Sector +5.48% --- ATH (7,108,668 vs 6,552,737)
NRx: 28,399 {vs 26,805; +5.95%} Sector +4.43% --- ATH (3,407,928 vs 3,216,643)
Ref: 30,840 {vs 27,801; +10.93%} Sector +6.45% --- ATH (3,700,740 vs 3,336,094)
GenL
TRx: 61,728 {vs 60,018; +2.85%} (7,407,358 vs 7,202,160)
NRx: 29,327 {vs 28,441; +3.12%} (3,519,259 vs 3,412,870)
L
TRx: 1,302 {vs 1,293; +0.71%} (156,258 vs 155,163)
NRx: 479 {vs 491; -2.38%} (57,514 vs 58,916)
V TRx Market Share: 48.45% vs 47.11% --- ATH
V NRx Market Share: 48.79% vs 48.09% --- ATH
V Ref Market Share: 48.14% vs 46.20% --- ATH
Scripts Update for Week Ending 03/05
Below the OLD scripts numbers as before, NOT NORMALIZED
ATH Across the Board in Numbers & Market Share except NRx Market Share which is 2nd ATH
Worth noting that Sector TRx reached a level never seen since early 2015
V
TRx: 45,748 {vs 42,348; +8.03%} Sector +5.69% --- ATH
NRx: 18,689 {vs 17,781; +5.11%} Sector +4.13% --- ATH
Ref: 27,059 {vs 24,567; +10.14 %} Sector +6.83% --- ATH
GenL
TRx: 47,750 {vs 46,082; +3.62%}
NRx: 19,968 {vs 19,332; +3.29%}
L
TRx: 861 {vs 845; +1.89%}
NRx: 282 {vs 283; -0.35%}
V TRx Market Share: 48.48% vs 47.44% --- ATH
V NRx Market Share: 48.00% vs 47.55% --- 2nd ATH – (ATH=48.02%)
V Ref Market Share: 48.83% vs 47.35% --- ATH
AMRN Partner in Canada Q1-Results & CEO Comments
""Q1 was a solid start to the year with good financial performance from our foundational products, positive new developments with Vascepa and the promising expansion of our product portfolio," said Greg Gubitz, CEO of HLS.
"Regarding Vascepa, we were granted priority review status by Health Canada, which could significantly reduce the timeline to bring this innovative therapy to Canadians. Subsequent to quarter-end, on April 29, 2019, we announced that we had filed our NDS for Vascepa with Health Canada."
"Also, during Q1, Amarin released new data from the REDUCE-IT™ trial, indicating that Vascepa reduced total major adverse cardiac events—first and subsequent—by 30% compared to placebo over a five-year period, which further demonstrates significant risk reduction with the product. In addition, in March, the American Diabetes Association issued updates to their Standards of Medical Care in Diabetes for 2019 stating that for patients with diabetes and atherosclerotic cardiovascular disease or other cardiac risk factors that are on a statin with controlled low density cholesterol (LDL-C), but elevated triglycerides (135-499), the addition of icosapent ethyl (Vascepa) should be considered to reduce cardiovascular risk. We are excited with the prospects for Vascepa and we believe that, if approved, it could ultimately generate revenue in Canada in a range of CDN $150-250 million per year. We believe this a conservative view and these new developments give us greater confidence in our outlook."
:):) JL
AMARIN vs COROMEGA & vs OMAX HEALTH Settlements
1) JOINT MOTION FOR ENTRY OF CONSENT ORDER (COROMEGA)
https://amarincorp.gcs-web.com/static-files/c036cb74-5453-479c-b5f3-4ea9124c5e89
2) [PROPOSED] CONSENT ORDER (COROMEGA)
https://amarincorp.gcs-web.com/static-files/b178e6f2-e394-44d8-a52e-2c3ca1ecc88c
3) Settlement Agreement and Mutual Release between Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland, LTD (“Amarin”) and The Coromega Company, Inc. (“Coromega”) May 3, 2019
https://amarincorp.gcs-web.com/static-files/262d4f7c-cc3c-4868-b114-48fee6693fcf
4) NOTICE OF SETTLEMENT IN PRINCIPLE AND STIPULATION TO STAY DEADLINES PENDING FINAL SETTLEMENT AGREEMENT (OMAX HEALTH INC.)
https://amarincorp.gcs-web.com/static-files/65ecb3f6-4162-43ac-b3bc-ba9288864bbf
5) What is Amarin doing to protect the Vascepa® franchise against dietary supplement manufacturers that mislead the public by referencing REDUCE-IT™ or Vascepa®? (updated May 3, 2019) -- AMARIN INVESTOR FAQ
https://investor.amarincorp.com/investor-faqs
NORMALIZED Scripts Update for Week Ending 26/04
V
TRx: 54,606 {vs 55,574; -1.74%} Sector +0.15% --- 4th ATH (6,552,737 vs 6,668,861)
NRx: 26,805 {vs 27,105; -1.10%} Sector -0.15% --- 8th ATH (3,216,643 vs 3,252,563)
Ref: 27,801 {vs 28,469; -2.35%} Sector +0.42% --- 3rd ATH (3,336,094 vs 3,416,298)
GenL
TRx: 60,018 {vs 58,899; +1.90%} (7,202,160 vs 7,067,911)
NRx: 28,441 {vs 28,196; +0.87%} (3,412,870 vs 3,383,508)
L
TRx: 1,293 {vs 1,272; +1.64%} (155,163 vs 152,662)
NRx: 491 {vs 519; -5.33%} (58,916 vs 62,236)
V TRx Market Share: 47.11% vs 48.01% ---4th ATH
V NRx Market Share: 48.09% vs 48.56% --- 4th ATH
V Ref Market Share: 46.20% vs 47.51% --- 3rd ATH
Scripts Update for Week Ending 26/04
Below the OLD scripts numbers as before, NOT NORMALIZED
V
TRx: 42,348 {vs 43,298; -2.19%} Sector -0.64% --- 4th ATH
NRx: 17,781 {vs 18,164; -2.11%} Sector -1.14% --- 8th ATH
Ref: 24,567 {vs 25,134; -2.26%} Sector -0.27% --- 4th ATH
GenL
TRx: 46,082 {vs 45,691; +0.86%}
NRx: 19,332 {vs 19,349; -0.09%}
L
TRx: 845 {vs 857; -1.40%}
NRx: 283 {vs 314; -9.87%}
V TRx Market Share: 47.44% vs 48.19% --- 4th ATH
V NRx Market Share: 47.55% vs 48.02% --- 5th ATH
V Ref Market Share: 47.35% vs 48.32% --- 4th ATH
Amarin (NASDAQ:AMRN): Q1 Non-GAAP EPS of -$0.05 beats by $0.05; GAAP EPS of -$0.07.
Revenue of $73.28M (+66.8% Y/Y) beats by $5.98M.
Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year
https://investor.amarincorp.com/node/16711/pdf
Thx BB & all, yup all good now
NORMALIZED Scripts Update for Week Ending 19/04
ATH Across the Board in Market Share
ATH in Refills Numbers, 2nd ATH in TRx Numbers
V
TRx: 55,574 {vs 55,759; -0.33%} Sector -1.44% --- 2nd ATH (6,668,861 vs 6,691,112)
NRx: 27,105 {vs 27,847; -2.67%} Sector -2.70% --- 5th ATH (3,252,563 vs 3,341,689)
Ref: 28,469 {vs 27,912; +2.00%} Sector -0.24% --- ATH (3,416,298 vs 3,349,423)
GenL
TRx: 58,899 {vs 60,419; -2.52%} (7,067,911 vs 7,250,321)
NRx: 28,196 {vs 28,996; -2.76%} (3,383,508 vs 3,479,498)
L
TRx: 1,272 {vs 1,262; +0.81%} (152,662 vs 151,440)
NRx: 519 {vs 528; -1.73%} (62,236 vs 63,332)
V TRx Market Share: 48.01% vs 47.48% ---ATH
V NRx Market Share: 48.56% vs 48.54% --- ATH
V Ref Market Share: 47.51% vs 46.46% --- ATH
Scripts Update for Week Ending 19/04
Below the OLD scripts numbers as before, NOT NORMALIZED
ATH in TRx & Refills Numbers – ATH Across the Board in Market Share
Short Week
V
TRx: 43,298 {vs 43,071; +0.53%} Sector -1.02% --- ATH
NRx: 18,164 {vs 18,483; -1.73%} Sector -2.64% --- 6th ATH
Ref: 25,134 {vs 24,588; +2.22%} Sector +0.19% --- ATH
GenL
TRx: 45,691 {vs 46,858; -2.49%}
NRx: 19,349 {vs 20,064; -3.56%}
L
TRx: 857 {vs 843; +1.66%}
NRx: 314 {vs 304; +3.29%}
V TRx Market Share: 48.19% vs 47.45% --- ATH
V NRx Market Share: 48.02% vs 47.57% --- ATH
V Ref Market Share: 48.32% vs 47.36% --- ATH
Scripts;
Sorry all due to an emergency I'm not @ the office today and won't be able to update scripts. Hopefully I'll be back by Monday / Tuesday